Bio Usawa and Rwandan Government Sign a Memorandum of Understanding to Manufacture Affordable Biologics in Africa
21. November 2024 12:46 ET
|
Bio Usawa Inc
Bio Usawa and the Rwanda Development Board have partnered to establish Rwanda’s first manufacturing plant for affordable treatments for serious eye disease
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
15. November 2024 01:00 ET
|
Sandoz Group
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for...
Alira Health Releases Global Report on Trends and Competitive Dynamics in the Biosimilar Market
29. Oktober 2024 09:00 ET
|
Alira Health
Framingham, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Alira Health, a global advisory and clinical research firm dedicated to humanizing life sciences, today announced the release of its 2024 Global...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
22. Oktober 2024 07:00 ET
|
Teva Pharmaceutical Industries Ltd
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
08. Oktober 2024 07:00 ET
|
Teva Pharmaceutical Industries Ltd
Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal womenTVB-009P, Teva’s proposed biosimilar to Prolia, showed...
Biopharmaceutical Market Size Projected to Reach USD 17,902.42 Billion by 2032 with 49.60% CAGR – SNS Insider
27. September 2024 09:24 ET
|
SNS Insider pvt ltd
Pune, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical Market Size & Growth Analysis: According to SNS Insider, The Biopharmaceutical Market Size was valued at USD 572.33 Billion in 2023...
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
22. Mai 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all...
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
30. April 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
22. April 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program...
Sandoz receives FDA approval for first and only denosumab biosimilars
05. März 2024 13:24 ET
|
Sandoz Group
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®*...